title: A Phase II Study of Adjuvant Chemotherapy of Tegafur-Uracil for Patients with Breast Cancer with HER2-negative Pathologic Residual Invasive Disease After Neoadjuvant Chemotherapy.
abstract: There is no consensus on the need for adjuvant chemotherapy for patients with pathological residual invasive breast cancer (non-pCR) after neoadjuvant chemotherapy (NAC). We evaluated the tolerability and safety of tegafur-uracil (UFT) as adjuvant chemotherapy for patients with human epidermal growth factor receptor 2-negative breast cancer that resulted in non-pCR after NAC.
  
  
  
  We treated patients with 270 mg/m2UFT per day for 2 years after definitive surgery and radiotherapy, if necessary. In cases with hormone-sensitive cancer, patients received concurrent endocrine therapy. The primary end-point was the rate of completion of scheduled UFT therapy. Secondary end-points included safety and disease-free survival.
  
  
  
  Twenty-one out of 29 patients (72%) completed the scheduled therapy. Eight patients discontinued the study treatment because of disease recurrence, toxicities, and patients' wish. Excluding liver dysfunction, adverse events were quite mild.
  
  
  
  Adjuvant UFT therapy after NAC was feasible and safe.
authors.affiliation: Breast Surgery, National Hospital Organization Osaka-Minami Medical Center, Kawachinagano, Japan sur112@osaka-med.ac.jp.
authors.forename: Satoru
authors.initials: S
authors.lastname: Tanaka
authors.affiliation: Breast and Endocrine Surgery, Osaka Medical College Hospital, Takatsuki, Japan.
authors.forename: Mitsuhiko
authors.initials: M
authors.lastname: Iwamoto
authors.affiliation: Breast and Endocrine Surgery, Osaka Medical College Hospital, Takatsuki, Japan.
authors.forename: Kosei
authors.initials: K
authors.lastname: Kimura
authors.affiliation: Breast and Endocrine Surgery, Hirakata City Hospital, Hirakata, Japan.
authors.forename: Yuko
authors.initials: Y
authors.lastname: Takahashi
authors.affiliation: Breast and Endocrine Surgery, Osaka Medical College Hospital, Takatsuki, Japan.
authors.forename: Hiyoya
authors.initials: H
authors.lastname: Fujioka
authors.affiliation: Breast Surgery, Saiseikai Suita Hospital, Suita, Japan.
authors.forename: Nayuko
authors.initials: N
authors.lastname: Sato
authors.affiliation: Breast and Endocrine Surgery, Osaka Medical College Hospital, Takatsuki, Japan.
authors.forename: Risa
authors.initials: R
authors.lastname: Terasawa
authors.affiliation: Breast and Endocrine Surgery, Osaka Medical College Hospital, Takatsuki, Japan.
authors.forename: Kanako
authors.initials: K
authors.lastname: Kawaguchi
authors.affiliation: Breast and Endocrine Surgery, Osaka Medical College Hospital, Takatsuki, Japan.
authors.forename: Ayana
authors.initials: A
authors.lastname: Ikari
authors.affiliation: Breast and Endocrine Surgery, Osaka Medical College Hospital, Takatsuki, Japan.
authors.forename: Tomo
authors.initials: T
authors.lastname: Tominaga
authors.affiliation: Breast and Endocrine Surgery, Osaka Medical College Hospital, Takatsuki, Japan.
authors.forename: Saki
authors.initials: S
authors.lastname: Maezawa
authors.affiliation: Breast and Endocrine Surgery, Osaka Medical College Hospital, Takatsuki, Japan.
authors.forename: Nodoka
authors.initials: N
authors.lastname: Umezaki
authors.affiliation: Breast and Endocrine Surgery, Osaka Medical College Hospital, Takatsuki, Japan.
authors.forename: Junna
authors.initials: J
authors.lastname: Matsuda
authors.affiliation: Breast and Endocrine Surgery, Osaka Medical College Hospital, Takatsuki, Japan.
authors.forename: Kazuhisa
authors.initials: K
authors.lastname: Uchiyama
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D011446:Prospective Studies; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
chemical_list: D005641:Tegafur; D014498:Uracil
keywords: Tegafur-uracil; breast cancer; neoadjuvant chemotherapy; pathologic complete response